Johnson & Johnson's RespiVert granted TopiVert exclusive rights to IP to discover and develop NSKIs for inflammatory diseases of the eye and gut

Johnson & Johnson

U.S. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

TopiVert Ltd.

U.K. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced